Levocarnitine

Why this drug is interesting

Valproate toxicity has two faces that do not correlate with the drug level. One is straightforward central nervous system depression after overdose, usually mild. The other is hyperammonaemic encephalopathy — a falling conscious level, focal deficits, cognitive slowing and increased seizure frequency — which occurs within the therapeutic range and is therefore missed for days in patients nobody thinks are poisoned.²³

Levocarnitine is given because valproate depletes carnitine, and carnitine is what routes valproate down the safe metabolic pathway. It is a mechanistic argument rather than an evidential one, and this page will say so repeatedly.

Pharmacology

The carnitine shuttle

Carnitine is an amino acid derivative synthesised endogenously from methionine and lysine. It is the essential cofactor for transporting long-chain fatty acids across the inner mitochondrial membrane for β-oxidation — without it, mitochondrial fatty acid metabolism stops.

What valproate does to it

Valproate is itself a branched-chain carboxylic acid. The 2009 review by Lheureux and Hantson sets out the mechanism:⁴

• Valproate is extensively metabolised by the liver via glucuronidation, mitochondrial β-oxidation and cytosolic ω-oxidation.
• Some of the ω-oxidation metabolites are implicated in its toxicity.
• Valproate inhibits carnitine biosynthesis by decreasing α-ketoglutarate concentration, and so may contribute to carnitine deficiency.
• It is postulated that carnitine supplementation increases β-oxidation of valproate, limiting cytosolic ω-oxidation and thereby the production of the toxic metabolites involved in liver injury and ammonia accumulation.
• Valproate hepatotoxicity and hyperammonaemic encephalopathy may be promoted either by pre-existing carnitine deficiency or by deficiency induced by valproate itself.

Who is at risk

Patients with carnitine deficiency or congenital urea cycle enzyme defects, notably ornithine transcarbamylase deficiency, are disproportionately affected — and valproate-induced hyperammonaemic encephalopathy is one of the classical ways an undiagnosed urea cycle disorder declares itself.²³ That is a reason to think about metabolic referral, not only about carnitine.

Dosing

Licensed oral dosing (carnitine deficiency, children under 12)

• Up to 200 mg/kg/day orally in 2–4 divided doses for chronic use in some disorders, with lower doses sufficing in others.¹
• "Higher doses of up to 400 mg/kg/day may be necessary in acute metabolic decompensation or the i.v. route may be required."¹
• Haemodialysis maintenance: 1 g/day orally, given at the end of the dialysis session; 1 g daily is the maximum for children as maintenance in secondary deficiency in dialysis.¹
• Monitor therapy by measuring free and acyl carnitine in both plasma and urine.¹

In valproate toxicity

Regimens in the literature are typically intravenous loading followed by divided maintenance doses, continued until the ammonia falls and the conscious level recovers. There is no consensus regimen and no controlled comparison; the 2009 review's own conclusion is that trials are needed "to better delineate the therapeutic and prophylactic roles of l-carnitine and the optimal regimen of administration".⁴ Use the poisons service.

Evidence

The honest summary is that the mechanism is well worked out, the clinical evidence is not, and the drug is used anyway because the risk is low.

What the reviews say

• Lheureux and Hantson (2009): "Some experimental and clinical data suggest that early intravenous supplementation with l-carnitine could improve survival in severe VPA-induced hepatotoxicity." Carnitine "has been shown to speed the decrease of ammonaemia" in valproate-induced encephalopathy — "although a correlation between ammonia concentrations and the clinical condition was not always observed".⁴
• The same review: "As it does not appear to be harmful, l-carnitine is commonly recommended in severe VPA poisoning, especially in children, although the clinical benefit in terms of liver protection or hastening of recovery from unconsciousness has not been established clearly."⁴
• Segura-Bruna et al. (2006): several studies "suggest that treatment with supplements of carnitine can lead to an early favorable clinical response" attributable to valproate-induced carnitine deficiency.²
• Wong et al. (2023), systematic review of 240 articles: hyperammonaemia is common and occurs within the therapeutic range; "with VPA discontinued, most symptomatic patients returned to baseline mental status with normalized ammonia level"; and further studies are required to guide management.³

What is not established

• No randomised controlled trial of levocarnitine in valproate toxicity exists.
• Ammonia concentration and clinical state do not reliably track together,⁴ so a falling ammonia is a weak surrogate.
• The 2023 review found insufficient data even to support routine ammonia monitoring in valproate-treated patients.³
• Prophylactic carnitine during valproate therapy in high-risk paediatric patients is "advocated"⁴ rather than demonstrated.

Safety

Levocarnitine is a physiological compound and the harm profile is correspondingly slight — which is a large part of why it is given.

Contraindication

Hypersensitivity to the active substance or excipients¹

Anticoagulation — the one to remember

"There have been very rare reports of International Normalised Ratio (INR) increased in patients treated concomitantly with levocarnitine and coumarinic drugs… INR — or other appropriate test of coagulation — should be checked weekly until they become stable, and monthly thereafter."¹ The anticoagulated patient with a valproate problem is not a rare combination

Hereditary fructose intolerance

The oral solution contains sorbitol: "Patients with hereditary fructose intolerance (HFI) should not take this medicinal product."¹ An absolute statement, not a caution — the same trap as the sorbitol content of idarucizumab

Hypoglycaemia

"While improving glucose utilisation, the administration of levocarnitine to diabetic patients receiving either insulin or hypoglycaemic oral treatment may result in hypoglycaemia. Plasma glucose levels in these subjects must be monitored regularly in order to adjust the hypoglycaemic treatment immediately, if required."¹ Relevant in the diabetic patient with a mixed overdose

Renal impairment

Safety and efficacy of oral levocarnitine have not been evaluated in renal insufficiency. Chronic high oral doses in severe renal impairment or end-stage renal disease on dialysis may accumulate the potentially toxic metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), normally excreted in urine. The label adds a clause that matters for this page: "This situation has not been observed following intravenous administration of levocarnitine."¹

Gastrointestinal

Nausea, vomiting, abdominal cramps and diarrhoea, with a characteristic fishy body odour from TMA. The label classes all four as very rare (<1/10,000) and notes they diminish on dose reduction;¹ the wider literature treats them as the usual dose-limiting effects of oral carnitine

Excipients

The oral solution also contains hydroxybenzoates (E217, E219), which may cause allergic reactions, possibly delayed.¹

Practical use in the ED

1. Consider valproate encephalopathy in any patient on valproate with reduced consciousness, increased seizure frequency, confusion or focal signs — including those with entirely therapeutic levels.
2. Send an ammonia (correctly — free-flowing sample, on ice, to the laboratory immediately) alongside valproate level, liver function, lactate, glucose and clotting.
3. Stop the valproate. This is the intervention with the best evidence behind it.³
4. Consider activated charcoal in acute oral overdose — the 2026 CTRC guideline recommends a single dose above an ingested 200 mg/kg, and an additional dose above 400 mg/kg to complete decontamination.⁵
5. Discuss levocarnitine with NPIS in severe poisoning, hepatotoxicity or hyperammonaemic encephalopathy, particularly in children — where the recommendation is strongest and the evidence no better.⁴
6. Start the pharmacy conversation immediately if intravenous levocarnitine is wanted. It is an unlicensed import.
7. Think about a urea cycle disorder in a child, or in an adult with recurrent unexplained hyperammonaemia, and involve the metabolic team.²
8. Consider haemodialysis in massive valproate overdose with severe acidosis, coma or very high levels — valproate is dialysable at toxic concentrations when protein binding saturates.

Critical appraisal

Levocarnitine sits at one end of a spectrum this batch of monographs illustrates well. At the other end is idarucizumab: a specific, immediate, mechanistically complete antidote with an unambiguous pharmacodynamic endpoint. Levocarnitine is a cofactor replacement for a deficiency that may or may not be present, aiming to shift metabolism between competing pathways, with an endpoint (ammonia) that does not reliably track the clinical state.

It is nonetheless a reasonable drug to give in severe valproate poisoning, and the reasoning is explicitly stated in the literature: "as it does not appear to be harmful, l-carnitine is commonly recommended".⁴ That is a legitimate argument in a rare, serious poisoning with a plausible mechanism and no alternative — but it is an argument from safety, not from efficacy, and it should be described as such rather than dressed up as an established antidote.

The regulatory position compounds the uncertainty. The UK licence covers a paediatric metabolic indication and an oral solution; the toxicological use is off-label, off-age and off-route, and depends on unlicensed importation. As with pyridoxine and pralidoxime, the practical constraint in an emergency is supply rather than pharmacology.

References

1. 1
   Levocarnitine Paediatric 30% Oral Solution alcohol free & sugar free — Summary of Product Characteristics, Aspire Pharma Ltd. electronic Medicines Compendium, product 9538. Sections 4.1–4.4. Source of the licensed indication (primary and secondary carnitine deficiency, children under 12, infants and newborns), the 200 and 400 mg/kg/day doses, the dialysis maintenance dose, the diabetic hypoglycaemia warning and the TMA/TMAO accumulation caution. Verified 31 Aug 2026. Only two levocarnitine products were listed on the emc, both oral paediatric solutions; a search for "Carnitor" returned no results, so there is no licensed UK intravenous levocarnitine.
2. 2
   Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J. Valproate-induced hyperammonemic encephalopathy. Acta Neurologica Scandinavica 2006;114(1):1–7. PubMed 16774619. Source of the carbamoyl phosphate synthetase I mechanism, the glutamine/astrocyte swelling pathway, the phenobarbital and topiramate contribution, the EEG description and the urea cycle disorder association.
3. 3
   Wong YJ, Fan J, Wan A, Mihic T, Gnyra M. Valproic acid-associated hyperammonemia: a systematic review. Journal of Clinical Psychopharmacology 2023;43(3):283–294. PubMed 37126830. 240 articles. Source of the prevalence ranges, the finding that hyperammonaemia occurs within the therapeutic range, the observation that most symptomatic patients recover on discontinuation alone, and the conclusion that further studies are needed to guide management.
4. 4
   Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clinical Toxicology (Philadelphia) 2009;47(2):101–111. PubMed 19280426. Source of the carnitine-depletion mechanism, the β-oxidation versus ω-oxidation argument, and the quoted statements on survival, ammonaemia and the absence of established clinical benefit. The quantitative claims on this page are limited to what appears in this abstract; no success-rate percentage is attributed to it.
5. 5
   Hoegberg LCG, Gosselin S, Buckley NA, Wood DM, et al. Recommendations from the Clinical Toxicology Recommendations Collaborative on the administration of activated charcoal in acute oral overdose. Clinical Toxicology 2026;64(6):419–475. PubMed 41906697. Table 4: valproic acid single-dose threshold 200 mg/kg, additional dose 400 mg/kg (both IR and MR), GRADE D. Full text read 4 Sep 2026.